SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Marco Randazzo, Josef Beatrice, Andreas Huber, Rainer Grobholz, Lukas Manka, Felix K. Chun, Franz Recker, Maciej Kwiatkowski, A “PSA Pyramid” for Men with Initial Prostate-specific Antigen ≤3 ng/ml: A Plea for Individualized Prostate Cancer Screening, European Urology, 2014,

    CrossRef

  2. 2
    Kirsten L. Greene, Sanoj Punnen, Peter R. Carroll, Evolution and Immediate Future of US Screening Guidelines, Urologic Clinics of North America, 2014, 41, 2, 229

    CrossRef

  3. 3
    Weranja K.B. Ranasinghe, Simon P. Kim, Nathan Lawrentschuk, Shomik Sengupta, Luke Hounsome, Jim Barber, Richard Jones, Paul Davis, Damien Bolton, Raj Persad, Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia, BJU International, 2014, 113, 1
  4. 4
    T. J. Wilt, P. T. Scardino, S. V. Carlsson, E. Basch, Prostate-Specific Antigen Screening in Prostate Cancer: Perspectives on the Evidence, JNCI Journal of the National Cancer Institute, 2014, 106, 3, dju010

    CrossRef

  5. 5
    Jeffrey D. Voigt, Stephen M. Zappala, E. Darracott Vaughan, Alan J. Wein, The Kallikrein Panel for prostate cancer screening: Its economic impact, The Prostate, 2014, 74, 3
  6. 6
    Declan G. Murphy, Thomas Ahlering, William J. Catalona, Helen Crowe, Jane Crowe, Noel Clarke, Matthew Cooperberg, David Gillatt, Martin Gleave, Stacy Loeb, Monique Roobol, Oliver Sartor, Tom Pickles, Addie Wootten, Patrick C. Walsh, Anthony J. Costello, The Melbourne Consensus Statement on the early detection of prostate cancer, BJU International, 2014, 113, 2
  7. 7
    H. Ballentine Carter, American Urological Association (AUA) Guideline on prostate cancer detection: process and rationale, BJU International, 2013, 112, 5
  8. 8
    Goutham Vemana, Gerald L. Andriole, Bad Habits May Be Hard to Break, European Urology, 2013, 63, 3, 426

    CrossRef

  9. 9
    Signe Benzon Larsen, Klaus Brasso, Peter Iversen, Jane Christensen, Michael Christiansen, Sigrid Carlsson, Hans Lilja, Søren Friis, Anne Tjønneland, Susanne Oksbjerg Dalton, Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort, European Journal of Cancer, 2013, 49, 14, 3041

    CrossRef

  10. 10
    H. K. Cho, H. B. Lim, Determination of prostate-specific antigen (PSA) tagged with TiO2 nanoparticles using ICP-MS, Journal of Analytical Atomic Spectrometry, 2013, 28, 4, 468

    CrossRef

  11. 11
    H. Ballentine Carter, Peter C. Albertsen, Michael J. Barry, Ruth Etzioni, Stephen J. Freedland, Kirsten Lynn Greene, Lars Holmberg, Philip Kantoff, Badrinath R. Konety, Mohammad Hassan Murad, David F. Penson, Anthony L. Zietman, Early Detection of Prostate Cancer: AUA Guideline, The Journal of Urology, 2013, 190, 2, 419

    CrossRef

  12. 12
    Axel Heidenreich, Per-Anders Abrahamsson, Walter Artibani, James Catto, Francesco Montorsi, Hein Van Poppel, Manfred Wirth, Nicolas Mottet, Early Detection of Prostate Cancer: European Association of Urology Recommendation, European Urology, 2013, 64, 3, 347

    CrossRef

  13. 13
    Tudor Borza, Ramdev Konijeti, Adam S. Kibel, Early Detection, PSA Screening, and Management of Overdiagnosis, Hematology/Oncology Clinics of North America, 2013, 27, 6, 1091

    CrossRef

  14. 14
    C. A. Haiman, D. O. Stram, A. J. Vickers, L. R. Wilkens, K. Braun, C. Valtonen-Andre, M. Peltola, K. Pettersson, K. M. Waters, L. L. Marchand, L. N. Kolonel, B. E. Henderson, H. Lilja, Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations, JNCI Journal of the National Cancer Institute, 2013, 105, 3, 237

    CrossRef

  15. 15
    Christopher J. Weight, Simon P. Kim, Debra J. Jacobson, Michaela E. McGree, R. Jeffrey Karnes, Jennifer St. Sauver, Men (Aged 40-49 Years) With a Single Baseline Prostate-specific Antigen Below 1.0 ng/mL Have a Very Low Long-term Risk of Prostate Cancer: Results From a Prospectively Screened Population Cohort, Urology, 2013, 82, 6, 1211

    CrossRef

  16. 16
    Siobhan Sutcliffe, Graham A. Colditz, Prostate cancer: is it time to expand the research focus to early-life exposures?, Nature Reviews Cancer, 2013, 13, 3, 208

    CrossRef

  17. 17
    D. L. J. Thorek, M. J. Evans, S. V. Carlsson, D. Ulmert, H. Lilja, Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection, Thrombosis and Haemostasis, 2013, 110, 3, 484

    CrossRef

  18. 18
    L. Esch, C. Arsov, P. Albers, PSA-gestützte Früherkennung, Der Onkologe, 2013, 19, 9, 705

    CrossRef

  19. 19
    Stacy Loeb, H. Ballentine Carter, William J. Catalona, Judd W. Moul, Fritz H. Schroder, Baseline Prostate-Specific Antigen Testing at a Young Age, European Urology, 2012, 61, 1, 1

    CrossRef

  20. 20
    Eric A. Klein, Ian M. Thompson, Chemoprevention of prostate cancer: an updated view, World Journal of Urology, 2012, 30, 2, 189

    CrossRef

  21. 21
    Die Ergebnisse der ERSPC 2012, Der Urologe, 2012, 51, 12, 1751

    CrossRef

  22. 22
    Allison S. Glass, Matthew R. Cooperberg, Peter R. Carroll, Early Detection of Prostate Cancer: More Information, More Clarity, European Urology, 2012, 62, 5, 753

    CrossRef

  23. 23
    Robert J. Klein, Christer Hallden, Amit Gupta, Caroline J. Savage, Anders Dahlin, Anders Bjartell, Jonas Manjer, Peter T. Scardino, David Ulmert, Peter Wallström, Andrew J. Vickers, Hans Lilja, Evaluation of Multiple Risk–Associated Single Nucleotide Polymorphisms Versus Prostate-Specific Antigen at Baseline to Predict Prostate Cancer in Unscreened Men, European Urology, 2012, 61, 3, 471

    CrossRef

  24. 24
    G. S. Sandhu, G. L. Andriole, Overdiagnosis of Prostate Cancer, JNCI Monographs, 2012, 2012, 45, 146

    CrossRef

  25. 25
    Johanna M. Mattsson, Ale Närvänen, Ulf-Håkan Stenman, Hannu Koistinen, Peptides binding to prostate-specific antigen enhance its antiangiogenic activity, The Prostate, 2012, 72, 14
  26. 26
    Andrew J. Vickers, Hans Lilja, Predicting prostate cancer many years before diagnosis: how and why?, World Journal of Urology, 2012, 30, 2, 131

    CrossRef

  27. 27
    G.L. Andriole, Prediction of Significant Prostate Cancer Diagnosed 20 to 30Years Later With a Single Measure of Prostate-Specific Antigen at or Before Age 50, Yearbook of Urology, 2012, 2012, 40

    CrossRef

  28. 28
    David D. Ørsted, Børge G. Nordestgaard, Gorm B. Jensen, Peter Schnohr, Stig E. Bojesen, Prostate-Specific Antigen and Long-Term Prediction of Prostate Cancer Incidence and Mortality in the General Population, European Urology, 2012, 61, 5, 865

    CrossRef

  29. 29
    Siobhan Sutcliffe, Ratna Pakpahan, Lori J. Sokoll, Debra J. Elliott, Remington L. Nevin, Steven B. Cersovsky, Patrick C. Walsh, Elizabeth A. Platz, Prostate-specific antigen concentration in young men: new estimates and review of the literature, BJU International, 2012, 110, 11
  30. 30
    Stacy Loeb, H. Ballentine Carter, William J. Catalona, Judd Moul, Fritz H. Schroder, Reply from Authors re: Seth A. Strope, Gerald L. Andriole. Prostate-Specific Antigen–Based Risk Assessment in Younger Men. Eur Urol 2012;61:8–9, European Urology, 2012, 61, 1, 9

    CrossRef

  31. 31
    Xiaoye Zhu, Peter C. Albertsen, Gerald L. Andriole, Monique J. Roobol, Fritz H. Schröder, Andrew J. Vickers, Risk-Based Prostate Cancer Screening, European Urology, 2012, 61, 4, 652

    CrossRef

  32. 32
    Andrew J. Vickers, Monique J. Roobol, Hans Lilja, Screening for Prostate Cancer: Early Detection or Overdetection?, Annual Review of Medicine, 2012, 63, 1, 161

    CrossRef

  33. 33
    Andrew J. Vickers, Hans Lilja, We Need a Better Marker for Prostate Cancer. How About Renaming PSA?, Urology, 2012, 79, 2, 254

    CrossRef

  34. 34
    N. Becker, Epidemiologie des Prostatakarzinoms, Der Radiologe, 2011, 51, 11, 922

    CrossRef

  35. 35
    A.S. Kibel, Prediction of Significant Prostate Cancer Diagnosed 20 to 30Years Later With a Single Measure of Prostate-Specific Antigen at or Before Age 50, Yearbook of Urology, 2011, 2011, 55

    CrossRef

  36. 36
    J. Noldus, Prostatakarzinom, Der Urologe, 2011, 50, S1, 171

    CrossRef

  37. 37
    Andrew J. Vickers, Hans Lilja, Urological cancer: Time for another rethink on prostate cancer screening, Nature Reviews Clinical Oncology, 2011, 9, 1, 7

    CrossRef

  38. 38
    Norman J. Maitland, The Future: What's in the Toolkit for Prostate Cancer Diagnosis and Treatment?,